April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Suppression of Ocular Scarring After Glaucoma Filtration Surgery in Rabbits by Activin Receptor-Like Kinase 5 Inhibitor
Author Affiliations & Notes
  • J. Sapitro
    Department of Ophthalmology, Summa Health System, Akron, Ohio
  • J. J. Dunmire
    Department of Ophthalmology, Summa Health System, Akron, Ohio
  • V. Sutariya
    Department of Pharmaceutical Sciences,
    Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio
  • W. J. Geldenhuys
    Department of Pharmaceutical Sciences,
    Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio
  • M. Hewit
    Department of Behavioral and Community Health Sciences,
    Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio
  • B. Y. J. T. Yue
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • H. Nakamura
    Department of Ophthalmology, Summa Health System, Akron, Ohio
    Department of Pharmaceutical Sciences,
    Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio
  • Footnotes
    Commercial Relationships  J. Sapitro, None; J.J. Dunmire, None; V. Sutariya, None; W.J. Geldenhuys, None; M. Hewit, None; B.Y.J.T. Yue, None; H. Nakamura, None.
  • Footnotes
    Support  American Health Assistance Foundation G2006-014 to HN and Summa Foundation Grant to HN
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 604. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Sapitro, J. J. Dunmire, V. Sutariya, W. J. Geldenhuys, M. Hewit, B. Y. J. T. Yue, H. Nakamura; Suppression of Ocular Scarring After Glaucoma Filtration Surgery in Rabbits by Activin Receptor-Like Kinase 5 Inhibitor. Invest. Ophthalmol. Vis. Sci. 2010;51(13):604.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Our laboratory has previously demonstrated that activin receptor-like kinase 5 (ALK-5) inhibitors are effective in suppressing expression of downstream, scarring-related proteins of transforming growth factor-β in cultured rabbit subconjunctival fibroblasts. The purpose of this study is to determine whether ALK-5 could suppress ocular scarring in vivo and thereby improve filtering bleb survival after glaucoma filtration surgery (GFS) in a rabbit model.

Methods: : ALK-5 inhibitor SB-505124 was used. In an in vivo rabbit GFS model, SB-505124 was delivered in a lactose tablet during the surgery. Eyes were examined by slit-lamp and the intraocular pressure (IOP) was measured until the time of bleb failure or up to 28 days after surgery. Paraffin sections from tissues collected on post surgery day 5 were histologically evaluated by hematoxylin and eosin staining. In addition, dissected subconjunctival tissues were placed in a cell culture flask with media and cell outgrowth from the explants was examined.

Results: : Filtering blebs in the GFS with SB-505124 (GFS-SB505124) group were maintained for more than 10 days (13.3 ± 4.2 days, n = 3), and the period of bleb survival was significantly longer than that in GFS controls (4.0 ± 1.0 days, n = 3, log rank = 11.801, p<0.01). Longer IOP reduction was also observed in the GFS-SB505124 group. Histologically, subconjunctival cell infiltration and scarring at the surgical site in the GFS-SB505124 (n = 2) and mitomycin (MMC, n = 2) groups were much subsided compared to GFS controls (n = 2). The conjunctival epithelium appeared to be thinner in the MMC group compared to that in the GFS-SB505124 and GFS controls. Subconjunctival blood vessels were noted in the GFS-SB505124 and control groups, but seldom in the MMC group. Cell outgrowth from explants dissected from eyes to which SB-505124 was applied during GFS was robust while outgrowth was poor from those treated with MMC.

Conclusions: : The ALK-5 inhibitor SB-505124 was efficacious in vivo in improving bleb survival with little toxicity. The inhibitor may provide a novel therapy for preventing ocular inflammation and scarring.

Keywords: wound healing • inhibitory receptors • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×